LQCL2604 - CMLE - MDA5 Antibody Testing: Rapid Results Required for Rapidly Progressive Interstitial Lung Disease

Course Description

LabQ 2026 Clinical Laboratory: Clinical Immunology

Faculty/Authors

Ryan Koo, MD¹, Eugene Krustev, MD^1,2,3, Cristina Moran-Toro, MD¹, Jacob J. E. Koopman, MD^4,5, Marvin J. Fritzler, MD PhD¹, May Y. Choi, MD MPH¹,³
¹Division of Rheumatology, Cumming School of Medicine
²Department of Microbiology, Immunology and Infectious Diseas
³McCaig Institute for Bone and Joint Health
University of Calgary
Alberta, Canada
⁴Erasmus Medical Center
Rotterdam, The Netherlands
⁵Department of Rheumatology, Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

CMLE Credit: 2.0

Estimated Completion Time: 2 hour

Format: Online Educational Activity and Post Exam

Instructions

To claim CMLE credit for the exercise, do the following:

Review the Technical Considerations.
Click Go to Course to view an overview of the modules in this course.
Click Access to begin the course.
Review the Educational Activity.
Complete and submit the Post Exam.
Submit the course Evaluation to register your credit.

Faculty Disclosures
The faculty have no relevant financial relationships with commercial interests to disclose.

Technical Considerations

Release Date: 3/31/2026
Review Date:
Expiration Date: 12/31/2028

Course Objectives

Following completion of this activity, you will be able to

recognize the heterogeneous presentations of anti-melanoma differentiation-associated gene 5 dermatomyositis (anti-MDA5 DM), including the most severe phenotype associated with rapidly progressive interstitial lung disease (RP-ILD);

identify biomarkers that can be used to predict disease course in anti-MDA5 DM;

describe the most common detection methods of anti-MDA5 and the urgency of testing in suspected anti-MDA5 RP-ILD; and

summarize the etiology, pathogenesis, diagnosis, and management of anti-MDA5 DM.

Summary

Availability:

On-Demand

Credit Offered:

2 CMLE Credits